Dr Saad Highlights Results Following the ACIS Study

02/20/2021

Fred Saad, MD, University of Montreal Hospital Center, discusses the findings of ACIS, a placebo-controlled, phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone versus abiraterone alone for chemotherapy-naive castration-resistant prostate cancer (CRPC).

Recent News

News

Atezolizumab Plus Cabozantinib Failed to Improve Survival Among Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 CONTACT-01 trial demonstrated that atezolizumab plus cabozantinib did not improve OS or PFS compared to docetaxel among patients with metastatic NSCLC who experienced disease progression after prior treatment.

Results from the phase 3...

04/09/2024

Oncology

News

Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.

Results from the phase 3 OPTICAL...

04/09/2024

Oncology

News

Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL

04/09/2024

Jordan Kadish

According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.

According to a phase 1/2 trial,...

04/09/2024

Oncology

News

Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma

04/09/2024

Amber Denham

According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.

According to phase 2 data, short...

04/09/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...

According to phase 3 data from...

04/09/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

The FDA granted accelerated...

04/08/2024

Oncology

News

Addition of Palbociclib to Fulvestrant Did Not Improve Progression-Free Survival Among Pre-Treated Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

04/04/2024

Stephanie Holland

According to results from the phase 2 PACE study, the addition of palbociclib to fulvestrant did not improve PFS among patients with HR-positive, HER2-negative metastatic breast cancer who experienced disease progression after treatment with...

According to results from the...

04/04/2024

Oncology

News

Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer

04/04/2024

Stephanie Holland

According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.

According to interim results...

04/04/2024

Oncology

News

Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy

04/03/2024

Stephanie Holland

According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...

According to results from the...

04/03/2024

Oncology

News

Hypomethylating Agents Plus Venetoclax Regimen Post-Allogeneic Hematopoietic Cell Transplant Relapse for Patients With AML

04/02/2024

Jordan Kadish

The combination of hypomethylating agents plus venetoclax post-allogeneic hematopoietic cell transplant relapse demonstrated efficacy among patients with acute myeloid leukemia, with possibly better outcomes among patients with NPM1 and IDH...

The combination of...

04/02/2024

Oncology